F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.
Fabien Zoulim,Claire Fournier,François Habersetzer,Martin F. Sprinzl,Stanislas Pol,Carla S. Coffin,Vincent Leroy,Mang Ma,Heiner Wedemeyer,Ansgar W. Lohse,Robert Thimme,Karine Lugardon,Perrine Martin,Bérangère Bastien,Benoit Sansas,N. Adda,Céline Halluard,Kaïdre Bendjama,Maud Brandely,Geneviève Inchauspé +19 more
TL;DR: In CHB patients under NUC, TG1050 exhibited a good safety profile and was capable to induce HBV-specific cellular immune response, which support further clinical evaluation, especially in combination studies.
Journal ArticleDOI
Progress in DNA vaccine for prophylaxis and therapy of hepatitis B.
TL;DR: Data showed even a more pronounced antiviral effect of DNA vaccine to DHBV envelope protein when associated with antiviral drug (lamivudine) treatment, and DNA-based vaccine appears as a promising new approach for prophylaxis and therapy of hepatitis B.
Journal ArticleDOI
Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?
TL;DR: New assays have been developed to study the functional consequences of polymerase mutations in HBV infection in terms of replication capacity and drug susceptibility, which should lead to the design and evaluation of rational treatment combinations for a better control of viral replication and prevention of drug resistance.
Journal ArticleDOI
Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
Ahmed Diab,Adrien Foca,Adrien Foca,Floriane Fusil,Thomas Lahlali,Thomas Lahlali,Pascal Jalaguier,Pascal Jalaguier,Fouzia Amirache,Lia N'Guyen,Lia N'Guyen,Nathalie Isorce,Nathalie Isorce,François-Loïc Cosset,François-Loïc Cosset,Fabien Zoulim,Ourania M. Andrisani,David Durantel,David Durantel +18 more
TL;DR: PLK1 is a proviral host factor that could be envisaged as a target for combined antiviral and antitumoral strategies against HBV infection and HBV‐mediated carcinogenesis.
Journal ArticleDOI
In Vitro Models for Studying Hepatitis B Virus Drug Resistance
TL;DR: The different in vitro models for the study of HBV resistance include enzymatic and cell-based assays and their relevance for the analysis of viral fitness, drug susceptibility, and cross-resistance is reviewed.